Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Insulin Efsitora Alfa→

Insulin Efsitora Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2131038-11-2
Molecular formula
C2810H4296N776O882S32
Molecular weight
64090 g/mol
Drug class
Long-acting basal insulin analogueantidiabetic hormone
Mechanism of action
Activates insulin receptors to regulate glucose metabolism, increasing peripheral glucose uptake (especially in skeletal muscle and adipose tissue) and suppressing hepatic glucose production. Its prolonged weekly action reflects reduced renal clearance, FcRn binding and reduced insulin-receptor affinity relative to human insulin.
Indications / reported uses
  • Improvement of glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e02229e-262c-4e25-9240-9e9de4eb7c1d · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-once-weekly-insulin-type-2-diabetes-mellitus · https://www.ema.europa.eu/en/medicines/human/EPAR/onswik

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Insulin Efsitora Alfa Environmental Risk Assessment (ERA) (the Insulin Efsitora Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.